| Identification | Back Directory | [Name]
DG-041 | [CAS]
861238-35-9 | [Synonyms]
DG-041
(E)-3-[1-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methylindol-7-yl]-N-(4,5-dichlorothiophen-2-yl)sulfonylprop-2-enamide
(2E)-3-[1-[(2,4-Dichlorophenyl)methyl]-5-fluoro-3-methyl-1H-indol-7-yl]-N-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propenamide
2-Propenamide, 3-[1-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methyl-1H-indol-7-yl]-N-[(4,5-dichloro-2-thienyl)sulfonyl]-, (2E)-
barrier,DG-041,blood-brain,Inhibitor,DG 041,inhibit,infarction,stroke,plaque,atherothrombosis,atherosclerotic,Prostaglandin Receptor,Myocardial,DG041 | [Molecular Formula]
C23H15Cl4FN2O3S2 | [MDL Number]
MFCD18251534 | [MOL File]
861238-35-9.mol | [Molecular Weight]
592.32 |
| Chemical Properties | Back Directory | [Melting point ]
236-238 °C | [density ]
1.57±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
3.55±0.10(Predicted) | [color ]
Light yellow to green yellow |
| Hazard Information | Back Directory | [Uses]
DG 041 (cas# 861238-35-9) is a useful research chemical.DG 041 inhibits the EP3 prostanoid receptor. It is being investigated as a potential agent for the treatment of atherothrombosis without inducing unwanted bleeding risk. | [in vivo]
DG-041 (1.78 mg/kg for intravenous or 9.62 mg/kg for oral) has t1/2 of 2.7 hours, 4.06 hours and Cmax of 9.46 μM, 2.74 μM for intravenous and oral administration, respectively. DG-041 has CL of 1250 mL/h/kg for intravenous[1]. | Animal Model: | Male SpragueDawley rat[1] | | Dosage: | 1.78 mg/kg (intravenous) or 9.62 mg/kg (oral) | | Administration: |
Intravenous or oral | | Result: | Had t1/2 of 2.7 hours, 4.06 hours and Cmax of 9.46 μM, 2.74 μM for intravenous and oral administration, respectively.
|
| [IC 50]
EP3: 4.6-8.1 nM (IC50) | [storage]
Store at -20°C |
|
| Company Name: |
R&D Systems, Inc
|
| Tel: |
18003437475 18003437475 |
| Website: |
www.rndsystems.com |
|